Trial Profile
Comparison of usefulness between denosumab and alendronate after teriparatide therapy in patients with glucocorticoid-induced osteoporosis (GIOP)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 31 Oct 2014
Price :
$35
*
At a glance
- Drugs Alendronic acid (Primary) ; Denosumab (Primary)
- Indications Corticosteroid-induced osteoporosis
- Focus Adverse reactions; Therapeutic Use
- 31 Oct 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 21 Jul 2014 New trial record